MedTrace Logo

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

NCT07650357 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-06-16

No results posted yet for this study

Summary

Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.

Conditions

  • Advanced Solid Tumor
  • Non Small Cell Lung Cancer
  • Pancreatic Carcinoma
  • Colorectal Cancer

Interventions

DRUG

CLSP-5282

CLSP-5282 to be administered by IV infusion

Sponsors & Collaborators

  • Clasp Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Lauren Harshman, MD · Clasp Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2029-05-31
Completion
2029-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07650357 on ClinicalTrials.gov